Savage Laboratories introduces DigiFab, a cheaper version of Digibind

Katharine Ristich

March 27, 2002

Wed, 27 Mar 2002 20:45:00

Melville, NY - Savage Laboratories has announced the introduction of DigiFab? (digoxin immune fab [Ovine]), a digoxin toxicity antidote, to the US marketplace. The drug has been determined by the FDA to be clinically equivalent to Digibind® (GlaxoSmithKline), yet DigiFab is available at roughly half of Digibind's average wholesale price, thanks to advances in the production process that allow the drug to be made quickly and easily in large volumes.

Digoxin toxicity is a potentially fatal disturbance of heart function, the company statement notes. "We are excited to be able to offer substantial savings for a life-saving treatment," said Perry Pedersen (Senior Director, Savage Laboratories).

Related links




Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.